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VIRAL HEPATIlISt
FOREWORD
The privilege of studying a disease over a span of almost two decades
is an unusual one. However, it is quite clear that an important factor en-
hancing the value of the experiences cited above was the opportunity of
working with a rather closely knit group whose interests and ideas were
intimately shared. Throughout the years, Dr. John R. Paul found himself
the central figure in this group; the influence of his quiet but unquench-
able enthusiasm has been, and is, an abiding strength during the numerous
frustrations. It was his responsibility to suggest when to alter the direction
of current investigations as often as it was to initiate or encourage new
ones; indeed, his perception and unerring sense of timing saved the day on
more than one occasion. It was he who in various parts of the world re-
turned again and again to a favorite pastime - the pursuit of clinical
epidemiology - and thereby clarified some of the problems of hepatitis.
In retrospect, it is no accident that this disease should have taken its
place among his dominant interests which include so many others, such as
scarlet fever, rheumatic fever, infectious mononucleosis, and poliomyelitis.
INTRODUCTION
The physicians and, in fact, all the people of this country have been made
painfully aware of the importance of viral hepatitis by reason of the
large military and civilian epidemics that have occurred here and in
various other parts of the world during and after World War II. These
epidemics were primarily concerned with infectious hepatitis (Virus A),
although a notable exception was the huge outbreak of serum hepatitis
(Virus B) in United States troops following their inoculation with yellow
fever vaccine (Table 1). Recognition of the rapidly growing role of
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the latter form of disease has evolved both here and abroad during the
past two decades as a natural sequence to the increasing opportunities
for artificial transmission of hepatitis viruses. At a meeting of the Expert
Advisory Committee on Hepatitis of the World Health Organization in
Belgium in 1952, cognizance was taken of the international impact of
both forms of disease and the problems they presented.' The introduction
of our medical profession, hitherto curiously naive in its appreciation
TABLE 1. MORBIDITY PER 1,000 AVERAGE STRENGTH PER YEAR FOR VIRAL
HEPATITIS (INFECTIOUs HEPATITIS AND SERUM HEPATITIS)
AMONG U. S. ARMY PERSONNEL, 1942-1953*
Date Total Army EUCOM FECOM Korea Cont. U.S.
1942 12.6 21.5 23.0 10.3
1943 3.6 6.8 2.8 0.6
1944 4.0 2.6 9.1 0.7
1945 11.1 9.4 43.8 6.4** 2.6
1946 4.5 6.7 6.4 5.3 3.1
1947 4.0 9.1 3.2 3.1 2.5
1948 3.7 12.7 3.8 6.0 1.8
1949 3.4 12.2 3.8 7.7 1.4
1950 4.5 12.3 10.4 19.0t 1.2
1951 4.9 7.8 13.7 16.9 1.4
1952 3.6 5.0 6.3 6.0 2.1
1953 2.7 3.6 4.3 3.7 1.7
*These data were obtained from summary reports and are to be considered
provisional.
** Includes data for September-December 1945 only.
tIncludes data for July-December 1950.
of viral hepatitis, was a rude but forceful one and was brought about by
the occurrence of some 200,000 cases in United States troops from 1942
to 1945. That we were not instantly prepared to meet this unexpected
situation might be partly explained by the facts that (i) this was the
first time that serum hepatitis had appeared as an important military disease
and (ii) the paucity of epidemic hepatitis in our troops in World War
I had not directed our attention to its possible importance, this despite
our historical background of 71,691 reported cases of jaundice among
white troops in the Union Army in the Civil War. It is, however, a tribute
to the energy and sagacity of military medical officers and their civilian
colleagues that a realistic appreciation of the problems soon came about.
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EPIDEMIOLOGY
Viral hepatitis has, in general, been a belated entry in the lists of
reportable diseases, although the cyclic recurrences of large epidemics at
irregular intervals of five to ten years or longer have been well documented
in many places in the world. Sweden and Denmark were pioneers in the
recognition of both forms of disease and in their epidemiology. The
statistical records of the latter country during the past thirty-three years
provide the longest and most accurate uninterrupted history of experience
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FIG. 1. These data were kindly supplied by Miss Marie Lindhardt, Chief of the
Statistical Section, the National Health Service of Denmark.
with epidemic hepatitis, which was made notifiable in Denmark in 1928.
From that time through 1960, 210,779 cases were reported. The rough
similarity of this figure with the number of cases reported in United States
troops in the short period 1942-1945 emphasizes the vast military im-
portance of the latter experience. In Denmark, two major epidemics oc-
curred; the first beginning in 1930 and reaching its peak in 1933, the
second beginning in 1941 and reaching its peak in 1943 (Fig. 1). It was
during this second, larger, outbreak that an unprecedented and as yet
unexplained sharp increase in mortality from liver disease occurred (18.7-
21.4 per 100,000 population), reflecting mainly the great increase in
lethality of hepatitis, particularly among older women (Fig. 2). Specula-
tion on the cause of this was largely concerned with factors in the host;
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however, there is some reason to suspect that changes in virulence of
virus might also be operative. Similar unexplained temporary increases
in lethality have been recorded in other countries. It is of interest that
this highly fatal form of acute hepatitis has largely disappeared from
Denmark, and the mortality has ranged from 0.2-0.7 per 100,000 popu-
lation for the past several years. That the mortality from liver disease
HEPATITIS EPIDEMICA, CIRRHOSIS HEPATIS
AND ALII MORBI HEPATIS IN DENMARK
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FIG. 2. These data were kindly supplied by Miss Marie Lindhardt, Chief of the
Statistical Section, the National Health Service of Denmark.
in Denmark in the years following the second epidemic has gradually
increased and remained at a substantially higher level, reflects largely
the increase in deaths due to cirrhosis. How many of these cases de-
veloped as a sequence to hepatitis is undetermined, although it is likely
that this was an important contributing factor. Bjorneboe' has stressed this
possibility, pointing out that the major increase in deaths from cirrhosis
has been among older women, the group recognized as being peculiarly
vulnerable to chronic progressive hepatitis.
Since the peak of the epidemic in 1943, the morbidity of hepatitis has,
with few exceptions, steadily declined in Denmark to 31.6 per 100,000
in 1960, the lowest annual rate ever reported. By contrast is the experience
of the United States in the past decade during which we have sustained
two large outbreaks; the first from 1953 to 1955, and the second be-
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ginning in 1959, reaching a rate of 23.1 per 100,000 population in 1960,
with a promise of an even higher rate in 1961 (Fig. 3). However, despite
these relatively sharp increases in morbidity in this country, our maximum
rates are greatly below those reported from other countries during periods
of high incidence and actually are similar to the current rate in Denmark.
Whether we actually have less hepatitis or less effective reporting is
VIRAL HEPATITIS IN THE UNITED STATES
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FIG. 3. The data used in preparing this chart were taken from
Surveillance Report, Number 4, March 21, 1961.
The CDC Hepatitis
not known, but it appears quite likely that we have more hepatitis in this
country than is evident from the figures.
HEPATITIS AND VOLUNTERS
Viral hepatitis is presently regarded by many as the infectious disease
presenting the greatest number of important unsolved problems. That this
may be true, however, does not reflect lack of interest, for over the past
two decades, in particular, many have tried their hands at unraveling the
mysteries that shroud the epidemiology, etiology, and pathogenesis of
this disease. Not a few of these secrets have been elucidated, and a con-
siderable store of information has been accumulated on the natural history
of hepatitis, its caustive agents, ways of spread, clinical course, and the
pathologic changes associated with it. Indispensable to the solution of many
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of these problems have been human volunteers, and their roles can never
be forgotten. The modern history of hepatitis is dominated by an array of
studies in which they participated, beginning in 1942 and continuing
interruptedly under the direction of several investigators up to the present
time.* For those who have shared these experiences, it can be said that they
were frequently harrowing, on occasion not without tragedy, but never
without dignity. Much is owed to the relatively small number of volunteers
who contributed so generously of themselves.
In retrospect, there appear to be three periods of maximal intensity of
activity in the studies with volunteers. The first was during and im-
mediately after World War II and was dominated by the pioneer work
of Oliphant, Paul, Stokes and Neefe, as well as Francis, and their
associates. These were exciting days, and many of the presently accepted
ideas about hepatitis came into being as a result of these studies that
were primarily concerned with properties of virus, routes of trans-
mission, period of infectivity, methods of prevention of disease, and
the relationship between infectious hepatitis and serum hepatitis. The
second period, in the early 1950's, was largely concerned with the fruit-
ful studies on the carrier state, particularly in serum hepatitis, by Murray
and also by Stokes and Capps and their associates. The third period began
in the late 1950's and is dominated by the highly productive and imaginative
work of Ward and Krugman and their associates. Unfortunately, unsolved
problems still loom mightily. The assiduous and often protracted attempts
over the years to develop a specific serological test and to propagate human
hepatitis viruses in any other medium except man were apparently
unrequited,' and the perusal of the numerous descriptions of these in-
vestigations reveals a dismal saga of poorly rewarded ventures. Again
and again over the years, several viruses, some identified and others as
yet unidentified, were found in patients with hepatitis, but their relation-
ship was never proved to be more than fortuitous. Each announcement was
followed by a flurry of activity in other laboratories that soon subsided
as its justification appeared impossible. Presently, however, a new wave of
excitement and hope follows the claims (published and unpublished)
of a number of investigators who have recently described the isolation in
tissue culture of apparently new agents from patients with hepatitis.'
One of these has been reported to produce hepatitis in volunteers after a
short incubation period,7 while another is neutralized by convalescent-
phase serums from patients with serum hepatitis.' The outcome of these
*Specific references to all of these studies may be found in earlier reviews"' or in
this paper.
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promising studies is eagerly awaited. Meanwhile, new interest has been
engendered in the possibility9 that chimpanzees may acquire infectious
hepatitis and transmit it to man.
STUDIES AT YALE UNIVERSITY SCHOOL OF MEDICINE
During the past two decades, many have had spasmodic and fitful
interests in viral hepatitis both here and abroad, but the infrequent
successes of investigations of many of the problems associated with this
disease were insufficient to hold for long any but the most curiously
devoted followers. However, in a few laboratories a steady and abiding
interest in hepatitis has been maintained, and in them and subsequently
in the laboratories of others formerly associated with them a continuity
of activity and association was preserved over the years.* It is appropriate
to point out that this continuance of interest was inspired largely and,
indeed, supported by the Army or Armed Forces, and it is of interest to
mention here that the ground work for the studies subsequently carried
out in the Department of Preventive Medicine at Yale University School
of Medicine under the supervision of Dr. John R. Paul was laid in Cairo
in November, 1943. Following a visit from Brigadier General J. S.
Simmons, Dr. Paul, then Director of the Commission on Neurotropic
Virus Diseases, AEB, was ordered from Cairo to Sicily to investigate
the epidemic of hepatitis that was ravaging Allied Forces. The hos-
pitals were filled with jaundiced men, and even the corridors of the
59th Evacuation Hospital, in Palermo, were crowded with beds for patients
with hepatitis. During this trip and subsequently back in the Middle
East, numerous specimens of serums and feces were collected. Unfor-
tunately, Dr. Paul was felled by hepatitis, inadvertently transmitted by
the injection of human serum as a part of an experiment with sandfly
fever some three months previously. It was his poor luck to be seriously
sick, and it was not until early February, 1944, that the trek was made
back to New Haven. The journey was not without incident; however, the
race against the disappearance of dry ice and thawing of specimens was
won over a tortuous route via Tunis, Rabat, Azores, and Washington. The
decision had been made to enlist the aid of volunteers, and a labora-
tory was established in New Haven to pursue these studies. Two hepatitis
viruses were recovered from the materials brought back from the Middle
*In addition to the investigators previously mentioned, it is appropriate to name
the following in this country: Drs. George Mirick, Frederik Bang, Werner and
Gertrude Henle, Robert McCollum, Alfred Evans, Victor Sborov, Cecil Watson, and
Paul Gyorgy.
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East. One of them (Virus A) came from a specimen of feces obtained from
an infantryman, hospitalized outside Cairo, who had come down with
hepatitis on the Anzio beachhead and produced the disease in volunteers
15 to 30 days after ingestion. The second strain of hepatitis virus (B)
came from a pool of serums from eleven men in the acute phase of sandfly
fever, in Cairo, and produced serum hepatitis in volunteers 60 to 90
days after parenteral inoculation. These two studies'0 initiated the work
in New Haven that was carried out there, and later in additional
laboratories, during the ensuing eighteen years under the sponsorship of
the Commission on Neurotropic Virus Diseases and subsequently its suc-
cessors, the Commission on Virus and Rickettsial Diseases and the Com-
mission on Viral Infections, and, the Commission on Liver Disease.
Following the cessation of war in Germany and during the early years
of the Occupation, the high incidence of hepatitis in our troops com-
manded continuing interest in this disease. A center for the care of
patients with hepatitis was established by the Army in 1947 at the
120th Station Hospital at Bayreuth, in an institution formerly used by
the German Luftwaffe; in 1949 it was transferred to the 98th General
Hospital in Munich. Dr. Paul and members of his group functioned in
a consultant capacity and furnished certain civilian personnel.* During
this period, numerous studies of an epidemiologic and clinical nature
were made in addition to continued unsuccessful attempts to transmit
hepatitis viruses to laboratory animals and tissue culture. For years,
these centers were vital sources of material that was sent back to this
country for use in virologic and serologic investigations. The frequent
trips to Germany for purposes of consultation furnished an unusual op-
portunity to observe the medical experiences of United States troops
against the background of the breath-taking, socio-economic changes that
took place in postwar Germany. As the number of our Occupation troops
diminished, and as the incidence of hepatitis subsided, the need for a
center was no longer apparent; in 1953, the center at Munich was closed
and patients with hepatitis were sent to the Army Hospital at Landstuhl.
However, despite the lessened frequency of disease, the Armed Forces
in Germany and elsewhere have continued to provide, right up to the
*The Hepatitis Research Team was formed here in 1947 and during the next three
years the following men acted as Clinical Directors: Drs. Horace T. Gardner, 1947-
1948; William E. Swift, Jr., 1948-1949; and James W. Colbert, 1949-1950. Dr. Doro-
thy M. Horstmann acted as Director of Virus Laboratory, 1949-1950. During 1950-
1952, the clinical investigations were largely the work of the Medical Staff of the 98th
General Hospital, and important in this group were Col. Robert S. Nelson, MC, Lt.
Col. Helmuth Sprinz, MC, and Capt. Alfred S. Evans, MC.
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present, a reason for numerous studies by members of the group asso-
ciated directly or indirectly with the laboratory at Yale University. In
addition, members of this group carried out a variety of studies on this
disease both here and abroad, including Japan, Korea, North Africa,
Turkey, India, and Italy.
FACTS AND FANCIES ABOUT HEPATITIS
It is not unexpected that during two decades of intensive work several
changes in thinking about hepatitis should occur; at times these changes
were clear-cut, but often it is not easy to mark the time or place where
one concept merged with another. For example, early studies"' appeared
to show that the administration of normal human gamma globulin prevented
epidemic hepatitis when the diagnosis was based on the presence of
jaundice. However, recent observations,'3 based on more subtle tests of
hepatic function, have indicated that the effect is modifying rather than
preventive since the incidence of anicteric hepatitis is not significantly
changed by the administration of gamma globulin. In addition, the earlier
observations suggested that as little as 0.01 ml./pound was effective, while
the recent results indicate that although this may be effective in children,
it is not sufficient in adults.
In regard to treatment, the pendulum has swung far as manifested by
reports of duration of hospitalization in certain groups of patients. In
1943-1944 in Egypt, the average period of hospitalization was thirty
days. Following the concern that developed in North Africa and Sicily
over relapse in patients rested for short periods, the duration of hos-
pitalization increased sharply to 50 days in the Mediterranean Theatre
in 1943-1945, 60 days in Germany in 1947-1949, and 89 days in Japan
in 1950-1951. This increase in loss of time was prompted largely by
fear of the development of relapse or chronic hepatitis and lack of
knowledge of the factors that potentiated them rather than by any recog-
nizable increase in severity of disease. The overconcern of medical officers
and civilian consultants that developed was attested by the incredulity
that greeted a suggestion made in 1950,14 based on observations at the
Hepatitis Center in Bayreuth, that patients with hepatitis could start
increased activity and return to duty sooner than hitherto expected. That
this seemingly "uncontrolled" observation was true, however, was borne
out by the results of subsequent studies conducted in Japan by Chalmers
et al.,' indicating that a somewhat less stringent program of rest was not
only possible but actually desirable. Even more difficult to overcome was the
"inherited" misapprehension that fats are poorly tolerated by patients
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with hepatitis. In spite of carefully controlled studies made years ago"
showing the desirability of dietary fats, particularly of dairy origin, there
apparently persists in the minds of many physicians almost a reflex aversion
to their use.
Early in World War II, it was not readily accepted by some that
hepatitis without jaundice ever occurred, and there were those who dis-
paraged the idea and spoke scornfully of "chemical hepatitis." How
far around the wheel has turned is now attested by the generally accepted
belief that anicteric hepatitis, especially among children, is far more
common than hepatitis with jaundice. Further exploration of this concept,
particularly in the light of recent studies by Ward and Krugman17 now
justifies the question whether the disease called hepatitis is actually
primarily a liver disease or, possibly, a generalized systemic disease in
which the liver need not always be involved.
Despite the fact that at least two strains of virus are known to cause
hepatitis, our concept of the variations of the disease they may produce
is rather limited and it is actually not known whether infection may not
occur, and possibly far more frequently without involvement of the
liver. Epidemic hepatitis is an acute enteric infection with generalized
systemic manifestations. Although the most striking and apparent effect
of hepatitis virus A in man is on the parenchymal cells of the liver, too
little is known about this virus to allow conclusive definition of the
pathogenesis of the disease it causes. The preponderance of gastrointestinal
complaints, as well as the roentgenographic and gastroscopic changes,
the pathologic findings at necropsy, the demonstration of virus in the
feces during the early days of illness and its transmission by feeding,
directed attention years ago to an alimentary phase of disease. Interest
in the importance of this phase and its relationship to multiplication and ex-
cretion of virus prompted a single experiment in the laboratory in New
Haven as long ago as 194518 when feces collected from experimentally
infected volunteers fifteen days before the onset of their disease were
fed to three other volunteers. None of these three men acquired hepatitis,
and the period of infectivity of the feces during the incubation period re-
mained unknown until 1958 when Ward and Krugmane7 again called
attention to the importance of the alimentary phase of disease on the
basis of results of their experiments that demonstrated the presence of virus
in the blood and feces of children 25 days after they had been fed virus
and two to three weeks before the appearance of jaundice at a time when
there were neither clinical manifestations nor abnormalities of hepatic
function. These observations were in keeping with the epidemiologic
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evidence that for years had suggested the importance of the asymptomatic
fecal carrier in the transmission of disease. Since virus apparently may
multiply in the gastrointestinal tract in this unobtrusive fashion without
any measurable impact on subjects who eventually come down with clinical
evidence of hepatitis, there is good reason to suspect that the initial
alimentary phase may, in a certain percentage of people, constitute the
whole expression of disease. That viremia was also present at this time is
of particular interest in relation to the subsequent demonstration of viremia
in another subject by Ward and Krugmane7 thirty-seven days after the
ingestion of virus at a time when he was asymptomatic but was believed to
have acquired epidemic hepatitis on the basis of a modest increase in the
serum transaminase as the only indication of hepatic involvement. Since
viremia occurs during the asymptomatic and biochemically normal alimen-
tary phase of the incubation period of a disease that eventually may
culminate in jaundice and since viremia also may be present at a time
appropriate for the onset of disease but actually without any evidence of it
except for a modest increase in serum transaminase, it does not require any
soaring of the imagination to conceive that a certain percentage of persons
who ingest hepatitis virus A may have only an alimentary infection and
viremia but without recognizable hepatic disease. That this could be more
common in extreme youth might be suggested by the apparent frequency of
hepatitis without jaundice in young children. Proof of the existence of
such a broad spectrum in type and severity of infection awaits the de-
velopment of a specific serologic test to measure the immunologic experience
in man.
The recently acquired information on the potential infectivity of
patients in the incubation period of epidemic hepatitis takes its place
in an interesting manner with what has been known for a long time
about serum hepatitis. Between 1944 and 1946, a series of observations
in Philadelphia and New Haven showed that strains of serum hepatitis
virus could be recovered from the blood of experimentally infected volun-
teers 87, 60, and 16 days before the onset of illness, when they had no
evidence of clinical disease nor abnormalities of hepatic function.`= The
factors that potentiate this curious prolonged equilibration between virus
and host in serum hepatitis and the factors that break it, making clinical
disease possible, are unknown. However, it may safely be presumed that
on many occasions no break in equilibration occurs and that viremia
persists for prolonged periods without any evidence of illness. The
imnportance of the asymptomatic carrier as the repository and medium for
transfer of serum hepatitis virus is generally appreciated.
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Recognition of the alimentary phase with viremia in epidemic hepatitis
and the prolonged period of viremia in serum hepatitis without any evi-
dence of hepatic dysfunction has raised the question whether the action
of virus itself produces hepatic damage if and when it occurs. Despite
the fact that descriptions of varying sized bodies visualized by electron
microscope in the liver cells of patients with acute hepatitis have ap-
peared, there is no conclusive evidence, as yet, that these represent
hepatitis virus. Indeed, the liver may be a poor place to seek hepatitis
virus, particularly after the onset of clinical disease when biopsies are
ordinarily made. The possibility has been suggested, and might be con-
sidered particularly in serum hepatitis, that the hepatic injury which
potentiates the appearance of jaundice is not only the result of direct
action of virus but also the result of the interaction of virus or some
product of tissue necrosis and the antibody evoked by it.'2 While there is
no proof positive for this speculation, reflection on certain hyperergic
manifestations of serum hepatitis, such as the occurrence of itching, hives,
arthralgia, and, on occasion, maculopapular rash on the legs before jaundice,
might prompt the suspicion that the hepatic injury is a similar mani-
festation. The apparent rarity of the classical histologic changes of adult
viral hepatitis in infancy and the fact that jaundice is uncommon in
hepatitis in early childhood but increases with age support the possibility
that maturation may be important in providing the conditions that result
in its appearance. In recent years, there has been a resurgence of interest
in the possibility that the development of chronic hepatitis is effected by
auto-antibodies. The serologic evidence that might be adduced to support
this concept has been recently reviewed' and it is indeed true that chronic
hepatic disease may flourish in a biologic environment containing auto-
antibodies. Popper et al. have demonstrated the presence of gamma globulin
by fluorescence microscopy in the livers of patients with chronic hepatitis,
and more recently they have described both nuclear and cytoplasmic binding
substances in the serums of patients with acute and chronic hepatic dis-
ease.' As yet, the real significance of all of these findings is not defined, and
it is impossible to say that auto-antibodies have a causative role in the
production of hepatic disease. Further investigations may clarify this
situation.
Among the numerous unsolved problems in viral hepatitis is the
relationship between the epidemic disease and serum hepatitis. It is
generally but not universally believed that the viruses causing them are
different and the differences between them are familiar to all. Experimen-
tally, Virus A has been found in the feces and blood and can be trans-
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mitted by feeding or parenteral inoculation, producing disease with a
short incubation period. In contrast, Virus B has been found only in the
blood and apparently can be transmitted only by parenteral inoculation.
Contact cases are common in the epidemic disease and rare in serum
hepatitis. Lastly, there is no cross immunity experimentally between
Virus A and Virus B, and in the field it was shown that men who had
had serum hepatitis were apparently even more susceptible to epidemic
hepatitis. It seems impossible not to admit that real differences exist
between these two viruses, yet it is of interest to speculate on how they
come about. Are they basically different viruses or does Virus A repre-
sent a master strain from which a number of strains of Virus B have
developed? Among the imponderabilities of Virus B is the concept that it
depends on the needle for survival. Despite the frequency of chance for
infection by this route, it would appear to be a precarious way of existence
unless there were some continuing source of supply of virus either by
other ways of transmission or emergence. Years ago in New Haven, it
was shown that Virus A inoculated parenterally was excreted in the feces'
- this has not been shown for Virus B; however, the rare occurrence
of hepatitis in wives of soldiers with serum hepatitis and the epidemic of
serum hepatitis described by Mirick et al.' in which contact cases appear
to have occurred suggest that this matter is not completely settled.
Of particular interest in this situation is the possibility that the survival
of Virus B actually depends not on the needle but on the continuing
emergence of new strains in man so that there is always available a new
source of supply. The more recently available information on the duration
of viremia in epidemic hepatitis makes it quite clear that infection with
Virus A may occur with little or no sign of hepatic disease. It had been
thought earlier, on the basis of experiments with volunteers, that in
those patients who had classical epidemic hepatitis with jaundice, the
presence of virus in the feces and blood was a limited experience, terminat-
ing early in the acute phase of disease.2 At all events, attempts to recover
virus from the feces and the blood four weeks, three months, and one
year after onset of disease were unsuccessful. Subsequent studies, how-
ever, showed that Virus A might remain in the feces as long as 5 to 16
months after the onset of disease.' It is entirely possible, and indeed
likely, that viremia also may persist in some patients, particularly in
those who have essentially an alimentary disease for prolonged periods.
Under such conditions, it is worthy of consideration that Virus A might
eventually undergo alterations that would condition a new behavior,
emerging with differences that are now regarded as characteristic of
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Virus B. Under certain circumstances, some previously held properties,
such as capacity for excretion in the feces after parenteral inoculation,
might be maintained in a limited fashion and account for the occasional
occurrence of apparent contact cases in serum hepatitis. In this way,
an ever-present source would be available for the evolution of strains
of Virus B from Virus A, guaranteeing its biologic survival, although its
transmission might be almost completely dependent on the needle.
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